Corrigendum to: GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma.

The author requested to add a co-author after the publication of the original article [1]. In this correction, the author has been added in the article entitled "GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma" in the journal "Current Drug Targets" 2021; 22(13), 1485-1495. Details of the error and a correction are provided here. The original editorial can be found online at 10.2174/1389450122666210204203950 We regret any errors and apologize to the readers. Original: Sitansu S. Nanda1, Md Imran Hossain1, Heongkyu Ju2 and Dong Kee Yi1,* 1Department of Chemistry, Myongji University, Yongin, 03674, South Korea; 2Department of Physics, Gachon University, Seongnam-si, Gyeonggi-do, South Korea Corrected: Sitansu S. Nanda1, Md Imran Hossain1, Heongkyu Ju2, Georgia C. Papaefthymiou3 and Dong Kee Yi1,* 1Department of Chemistry, Myongji University, Yongin, 03674, South Korea; 2Department of Physics, Gachon University, Seongnam-si, Gyeonggi-do, South Korea 3Department of Physics, Villanova University, Villanova, Pennsylvania19085, USA.

GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma.

BACKGROUND: Glycogen syntheis kinase (GSK-3) inhibitors are novel therapeutic agents for treating various types of cancer, such as breast, lung, and gastric cancer. No pathological changes have been found by the morphological examination of GSK-3. OBJECTIVES: This review describes recent procedures using GSK-3 inhibitors, primarily in treating colon carcinoma. Furthermore, it also explains the mechanism of action of different GSK-3 inhibitors in treating various types of cancers and proposes some additional mechanisms may be useful for further research on GSK-3 inhibitors for cancers, including colon carcinoma. RESULTS: The majority of the cancerous and pre-cancerous lesions are stimulated by the transformation of membrane-bound arachidonic acid (AA) to eicosanoids, a transformation that promotes for the viability, proliferation, and spread of cancer. GSK-3 inhibitors can reinstate hostility to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) responsiveness in gastric adenocarcinoma cells. GSK-3, the final enzyme in glycogen synthesis, is a serine/threonine kinase that phosphorylates varied sequences that are more than a hundred in number, within proteins in an array of heterogeneous pathways. It is an essential module of an exceptionally large number of cellular processes, playing a fundamental role in many metabolic processes and diseases. Many patients diagnosed with colon cancer achieve long-term remission with outstanding survival through the GSK-3 inhibitors. CONCLUSION: Prior to the extensive application of these proposed mechanisms of GSK-3 inhibitor, further evaluation and clinical studies are needed. Only after the completion of appropriate clinical studies and morphological examinations, would extensive application be apprpriate.

Hydroxyapatite-alginate Based Matrices for Drug Delivery.

BACKGROUND: Hydroxyapatite (HAp) is a biocompatible bioceramic compound by nature and widely utilized in a broad range of biomedical applications, especially in drug delivery, tissue engineering, orthopedics, dentistry, etc. To intensify its usage, HAp is being reinforced with different biopolymer(s). In these bioceramicbiopolymeric systems, HAp crystallites have been well inviolate with the alginate molecules. The objective of this review article is to present a comprehensive discussion of different recently researched drug-releasing potential by HAp-alginate based matrices. METHODS: During past few years, HAp particles (both synthesized and naturally derived) have been reinforced within different alginate-based systems to load a variety of drug candidates. Most of the reported drug-releasing HAp-alginate based matrices were prepared by the methodology of ionic-gelation of sodium alginate followed by air-drying/spray drying process. RESULTS: HAp-alginate systems have already been proved as useful for loading a variety of drugs and also resulting sustained drug delivery with minimizing the drawbacks of pure alginate matrices (such as burst drug-releasing and low mechanical property in the alkaline pH). CONCLUSION: HAp-alginate composites loaded with different kinds of drugs have already been reported to exhibit sustained releasing of loaded drugs over a longer period.